BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Biotech Bay

  $100M Richer, Neuron23 Introduces LRRK2 inhibitor for Parkinson’s

  Neuron23 announced today that it closed a $100 million Series C financing round led by SoftBank Vision Fund 2.

  March 30, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Roche Strikes Out in Difficult-to-Treat Small-Cell Lung Cancer

  Interim data from Genentech’s first randomized study on a candidate treatment for extensive-stage small-cell lung cancer failed to meet its co-primary endpoint.

  March 30, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  COVID-19 Update: Adagio Gunning for EUA and mRNA Boosters Recommended

  Although it looks that we’re on the downside of the COVID-19 pandemic in the U.S., biopharma companies are still working on developing better treatments and preventions.

  March 30, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Vyant Bio and Organo Therapeutics Join Forces to Solve Parkinson’s

  Vyant Bio and OrganoTherapeutics announced a new partnership between them, with plans to advance research and development efforts in the treatment of Parkinson’s Disease.

  March 30, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS
• 

  Business

  BioNTech Set to Join Ranks of Largest Drugmakers in the World

  After manufacturing more than 2.6 billion doses of the Comirnaty COVID-19 vaccine together, Pfizer’s partner BioNTech is reporting skyrocketing profits.

  March 30, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  Pursuit of Scientific Challenges Drives New CODA CSO Susan Catalano

  Susan Catalano, Ph.D., joined CODA Biotherapeutics as chief scientific officer after 14 years as CEO of Cognition Therapeutics, the company she founded in 2007 and took public in 2021.

  March 30, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  BioMidwest

  Study: Preclinical Mouse Model Shows Cognitive Improvement in Down Syndrome

  Partner Therapeutics, based in Lexington, Mass., has teamed up with the University of Colorado to study mouse models of Down syndrome and compounds that might improve memory with age.

  March 30, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Oscars Slap Shines New Spotlight on Alopecia Areata

  Despite being represented in clinical research, no solutions have been found to circumvent the effects of Alopecia areata. However, there may be hope.

  March 30, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Employer Resources

  How to Manage Gen Z Employees in the Biopharma Industry

  Successfully managing Gen Z employees in the workplace requires knowing about their distinctive traits and the factors that set them apart.

  March 30, 2022

   · 

  5 min read

   · 

  Brandi Marcene
• 

  Drug Development

  Study Suggests Far-UV Light Could Save Us from the Next Pandemic

  Researchers have developed a new form of UV light that is safe for people but decreased the level of indoor airborne microbes by more than 98% in less than five minutes.

  March 30, 2022

   · 

  3 min read

   · 

  Mark Terry